12:48 PM
 | 
Feb 08, 2019
 |  BC Week In Review  |  Company News  |  Deals

Lilly dropping Hanmi's BTK inhibitor

Eli Lilly and Co. (NYSE:LLY) discontinued from its pipeline a Bruton's tyrosine kinase (Btk) inhibitor it had licensed from Hanmi Pharmaceutical Co. Ltd. (KSE:128940). The pharma...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >